ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO029

Risk Factors for AKI in Patients With COVID-19 in Two University Hospital of Colombia

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Contreras, Kateir, Hospital Universitario San Ignacio, Bogota, Colombia
  • Barbosa Silva, Oscar Ricardo, Pontificia Universidad Javeriana, Bogota, Colombia
  • Munoz, Ana Cecilia, Pontificia Universidad Javeriana, Bogota, Colombia
  • Suarez, Juan Sebastian, Universidad Nacional de Colombia, Bogota, Bogota, Colombia
  • Gonzalez, Camilo A., Hospital Universitario San Ignacio, Bogota, Colombia
  • Rodriguez, Patricia, Pontificia Universidad Javeriana, Bogota, Colombia
  • Valderrama Rios, Martha C., Universidad Nacional de Colombia, Bogota, Bogota, Colombia
  • Garcia, Paola, Pontificia Universidad Javeriana, Bogota, Colombia
  • Vargas angel, Diana Carolina, Hospital Universitario San Ignacio, Bogota, Colombia
  • Cortes, Jorge Alberto, Universidad Nacional de Colombia, Bogota, Bogota, Colombia

Group or Team Name

  • COVAKI
Background

Patients with COVID-19 have a high incidence of acute kidney injury (AKI), which is associated with mortality. The objetive of our study is to know the factors associated with AKI, to manage the level of care and health resources according to risk.

Methods

We design an observational retrospective cohort study in 2 hospitals in Bogotá, Colombia. Adults hospitalized for > 48 hours between March 2020 and March 2021, with confirmed SARS-CoV-2 infection. The main outcome was incidence of AKI during the first 28 days from admission. A descriptive analysis of the sociodemographic and clinical characteristics of the study population was performed . Univariate and bivariate analysis and multivariate logistic regression model was conducted for the outcome AKI.

Results

We included 1584 patients, 60.4% male, 46.8% older than 65 years. The incidence of AKI was 46.5%, stage 1 in 60.7%, Stage 2 in 15.7%, and stage 3 in 23.6%. Renal replacement therapy was performed in 11.1% of patients with AKI. Table 1 summarizes cohort characteristics and the bivariate analysis. In the multivariate analysis, sex, age, hypertension, CKD, treatment with oral antidiabetics, diuretics, statins, qSOFA, platelet count, CRP, D-dimer, treatment with vancomycin, piperacillin tazobactam, requirement of vasopressor support were realated with AKI. The interactions antihypertensive /diuretics, PAFI /Requirement of invasive mechanical ventilation, Hypertension /antihypertensives, were associated with AKI (P value <0.5). Hospital crude mortality for AKI was 45.5% versus 11.7% without AKI (p<0.0001)

Conclusion

AKI is frequent in patients hospitalized with COVID 19, conventional risk factors are the rule, we denote other known markers of severity for COVID-19 in association with AKI. These results allowed us to manage the hospital resource